Anika Therapeutics (ANIK) 10-Q 8 Aug 23 2023 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Jul. 31, 2023
Document Information [Line Items]
Entity Central Index Key	0000898437
Entity Registrant Name	Anika Therapeutics, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-14027
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3145961
Entity Address, Address Line One	32 Wiggins Avenue
Entity Address, City or Town	Bedford
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01730
City Area Code	781
Local Phone Number	457-9000
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ANIK
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		14,631,112

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 65,071	$ 86,327
Accounts receivable, net	36,737	34,627
Inventories, net	42,604	39,765
Prepaid expenses and other current assets	7,789	8,828
Total current assets	152,201	169,547
Property and equipment, net	47,988	48,279
Right-of-use assets	29,631	30,696
Other long-term assets	19,390	17,219
Deferred tax assets	1,498	1,449
Intangible assets, net	70,707	74,599
Goodwill	7,467	7,339
Total assets	328,882	349,128
Current liabilities:
Accounts payable	7,944	9,074
Accrued expenses and other current liabilities	15,512	18,840
Total current liabilities	23,456	27,914
Other long-term liabilities	401	398
Deferred tax liability	3,235	6,436
Lease liabilities	27,775	28,817
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	0	0
Common stock, $0.01 par value; 90,000 shares authorized, 14,816 issued and 14,657 outstanding and 14,625 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	147	146
Additional paid-in-capital	82,397	81,141
Accumulated other comprehensive loss	(6,157)	(6,443)
Retained earnings	197,628	210,719
Total stockholders’ equity	274,015	285,563
Total liabilities and stockholders’ equity	$ 328,882	$ 349,128

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares shares in Thousands	Jun. 30, 2023	Dec. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,250	1,250
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	90,000	90,000
Common stock, shares issued (in shares)	14,816	14,625
Common stock, shares outstanding (in shares)	14,657	14,625

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue	$ 44,302	$ 39,657	$ 82,226	$ 76,350
Cost of revenue	15,330	14,795	30,411	29,684
Gross Profit	28,972	24,862	51,815	46,666
Operating expenses:
Research and development	8,914	6,975	17,314	13,132
Selling, general and administrative	23,689	21,268	50,685	40,469
Total operating expenses	32,603	28,243	67,999	53,601
Loss from operations	(3,631)	(3,381)	(16,184)	(6,935)
Interest and other income (expense), net	561	96	1,100	(58)
Loss before income taxes	(3,070)	(3,285)	(15,084)	(6,993)
Benefit from income taxes	(329)	(442)	(1,993)	(1,217)
Net income (loss)	$ (2,741)	$ (2,843)	$ (13,091)	$ (5,776)
Net loss per share:
Basic (in dollars per share)	$ (0.19)	$ (0.20)	$ (0.89)	$ (0.40)
Diluted (in dollars per share)	$ (0.19)	$ (0.20)	$ (0.89)	$ (0.40)
Weighted average common shares outstanding:
Basic (in shares)	14,688	14,555	14,671	14,511
Diluted (in shares)	14,688	14,555	14,671	14,511
Net income (loss)	$ (2,741)	$ (2,843)	$ (13,091)	$ (5,776)
Foreign currency translation adjustment	14	(847)	286	(928)
Comprehensive loss	$ (2,727)	$ (3,690)	$ (12,805)	$ (6,704)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Restricted Stock Units (RSUs) [Member] Common Stock Outstanding [Member]	Restricted Stock Units (RSUs) [Member] Additional Paid-in Capital [Member]	Restricted Stock Units (RSUs) [Member] Retained Earnings [Member]	Restricted Stock Units (RSUs) [Member] AOCI Attributable to Parent [Member]	Restricted Stock Units (RSUs) [Member]	Common Stock Outstanding [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2021						14,441
Balance at Dec. 31, 2021						$ 144	$ 67,081	$ 225,578	$ (5,718)	$ 287,085
Issuance of common stock for equity awards (in shares)						1
Issuance of common stock for equity awards						$ 0	15	0	0	15
Vesting of restricted stock units (in shares)	106
Vesting of restricted stock units	$ 1	$ (1)	$ 0	$ 0	$ 0
Stock-based compensation expense						$ 0	2,545	0	0	2,545
Retirement of common stock for minimum tax withholdings (in shares)						(30)
Retirement of common stock for minimum tax withholdings						$ 0	(844)	0	0	(844)
Net income (loss)						0	0	(2,933)	0	(2,933)
Other comprehensive income (loss)						0	0	0	(81)	(81)
Stock-based compensation expense						$ 0	2,545	0	0	2,545
Balance (in shares) at Mar. 31, 2022						14,518
Balance at Mar. 31, 2022						$ 145	68,796	222,645	(5,799)	285,787
Balance (in shares) at Dec. 31, 2021						14,441
Balance at Dec. 31, 2021						$ 144	67,081	225,578	(5,718)	287,085
Net income (loss)										(5,776)
Balance (in shares) at Jun. 30, 2022						14,598
Balance at Jun. 30, 2022						$ 146	72,851	219,802	(6,646)	286,153
Balance (in shares) at Mar. 31, 2022						14,518
Balance at Mar. 31, 2022						$ 145	68,796	222,645	(5,799)	285,787
Vesting of restricted stock units (in shares)	61
Vesting of restricted stock units	$ 1	(1)	0	0	0
Stock-based compensation expense						$ 0	4,081	0	0	4,081
Retirement of common stock for minimum tax withholdings (in shares)						(1)
Retirement of common stock for minimum tax withholdings						$ 0	(25)	0	0	(25)
Net income (loss)						0	0	(2,843)	0	(2,843)
Other comprehensive income (loss)						$ 0	0	0	(847)	(847)
Issuance of ESPP shares (in shares)						20
Issuance of ESPP shares						$ 0	0	0	0	0
Stock-based compensation expense						$ 0	4,081	0	0	4,081
Balance (in shares) at Jun. 30, 2022						14,598
Balance at Jun. 30, 2022						$ 146	72,851	219,802	(6,646)	286,153
Balance (in shares) at Dec. 31, 2022						14,625
Balance at Dec. 31, 2022						$ 146	81,141	210,719	(6,443)	285,563
Issuance of common stock for equity awards (in shares)						1
Issuance of common stock for equity awards						$ 0	7	0	0	7
Vesting of restricted stock units (in shares)	177
Vesting of restricted stock units	$ 2	(2)	0	0	0
Stock-based compensation expense						$ 0	3,717	0	0	3,717
Retirement of common stock for minimum tax withholdings (in shares)						(62)
Retirement of common stock for minimum tax withholdings						$ (1)	(1,620)	0	0	(1,621)
Net income (loss)						0	0	(10,350)	0	(10,350)
Other comprehensive income (loss)						0	0	0	272	272
Stock-based compensation expense						$ 0	3,717	0	0	3,717
Balance (in shares) at Mar. 31, 2023						14,741
Balance at Mar. 31, 2023						$ 147	83,243	200,369	(6,171)	277,588
Balance (in shares) at Dec. 31, 2022						14,625
Balance at Dec. 31, 2022						$ 146	81,141	210,719	(6,443)	285,563
Net income (loss)										(13,091)
Balance (in shares) at Jun. 30, 2023						14,657
Balance at Jun. 30, 2023						$ 147	82,397	197,628	(6,157)	274,015
Balance (in shares) at Mar. 31, 2023						14,741
Balance at Mar. 31, 2023						$ 147	83,243	200,369	(6,171)	277,588
Issuance of common stock for equity awards (in shares)						1
Issuance of common stock for equity awards						$ 0	30	0	0	30
Vesting of restricted stock units (in shares)	70
Vesting of restricted stock units	$ 1	$ (1)	$ 0	$ 0	$ 0
Stock-based compensation expense						$ 0	4,150	0	0	4,150
Retirement of common stock for minimum tax withholdings (in shares)						(16)
Retirement of common stock for minimum tax withholdings						$ 0	(432)	0	0	(432)
Net income (loss)						0	0	(2,741)	0	(2,741)
Other comprehensive income (loss)						$ 0	0	0	14	14
Issuance of ESPP shares (in shares)						20
Issuance of ESPP shares						$ 0	456	0	0	456
Stock-based compensation expense						$ 0	4,150	0	0	4,150
Repurchase of common stock (in shares)						(159)
Repurchase of common stock						$ (1)	(5,049)	0	0	(5,050)
Balance (in shares) at Jun. 30, 2023						14,657
Balance at Jun. 30, 2023						$ 147	$ 82,397	$ 197,628	$ (6,157)	$ 274,015

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net income (loss)	$ (13,091)	$ (5,776)
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	3,210	3,435
Amortization of acquisition related intangible assets	3,891	3,891
Non-cash operating lease cost	1,086	797
Stock-based compensation expense	7,867	6,626
Deferred income taxes	(3,277)	(2,020)
Provision for credit losses	103	175
Provision for inventory	1,252	675
Changes in operating assets and liabilities:
Accounts receivable, net	(2,116)	(3,103)
Inventories	(6,152)	(1,541)
Prepaid expenses, other current and long-term assets	756	(948)
Accounts payable	(1,029)	284
Operating lease liabilities	(1,048)	(764)
Accrued expenses, other current and long-term liabilities	(3,648)	(1,169)
Income taxes	285	657
Net cash (used in) provided by operating activities	(11,911)	1,219
Cash flows from investing activities:
Purchases of property and equipment	(2,846)	(3,266)
Net cash used in investing activities	(2,846)	(3,266)
Cash flows from financing activities:
Proceeds from employee stock purchase program	456	0
Cash paid for tax withheld on vested restricted stock awards	(2,049)	(870)
Proceeds from exercises of equity awards	37	15
Payments made on finance leases	0	(53)
Repurchases of common stock	(5,000)	0
Net cash used in financing activities	(6,556)	(908)
Exchange rate impact on cash	57	(39)
Decrease in cash and cash equivalents	(21,256)	(2,994)
Cash and cash equivalents at beginning of period	86,327	94,386
Cash and cash equivalents at end of period	65,071	91,392
Non-cash investing activities:
Right-of-use assets obtained in exchange for operating lease liabilities	0	11,589
Purchases of property and equipment included in accounts payable and accrued expenses	$ 60	$ 680

Note 1 - Nature of Business

Note 1 - Nature of Business	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Nature of Operations [Text Block]	1. Nature of Business Anika Therapeutics, Inc. (the “Company”) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis (“OA”) pain management, regenerative solutions, sports medicine and Arthrosurface joint solutions. In early 2020, 30 The Company is subject to risks common to companies in the life sciences industry including, but not

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been or omitted pursuant to SEC rules and regulations relating to interim financial statements. The December 31, 2022 The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s annual financial statements filed with its Annual Report on Form 10 December 31, 2022. three six June 30, 2023 not December 31, 2023. Segment Information Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker as of June 30, 2023 280, Segment Reportin one

Note 3 - Accounts Receivable

Note 3 - Accounts Receivable	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Accounts and Nontrade Receivable [Text Block]	3. Accounts Receivable The Company estimates an allowance for credit losses with its accounts receivable resulting from the inability of its customers to make required payments, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations. In determining the adequacy of the allowance, management specifically analyzes individual accounts receivable, historical bad debts, customer concentrations, customer creditworthiness, current and reasonable and supportable forecasts of future economic conditions, accounts receivable aging trends, and changes in the Company’s customer payment terms. The components of the Company’s accounts receivable are as follows: As of As of June 30, December 31, 2023 2022 Accounts Receivable $ 38,357 $ 36,235 Less: Allowance for credit losses 1,620 1,608 Net balance, end of period $ 36,737 $ 34,627 A summary of activity in the allowance for credit losses is as follows: As of June 30, 2023 2022 Balance, beginning of the period $ 1,608 $ 1,442 Amounts provided 241 226 Amounts recovered (138 ) (48 ) Amounts written off (103 ) (111 ) Translation adjustments 12 (104 ) Balance, end of period $ 1,620 $ 1,405

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4. Fair Value Measurements The Company has certain cash equivalents in money market funds that are classified within Level 1 not no six June 30, 2023 2022. The classification of the Company’s cash equivalents within the fair value hierarchy was as follows: June 30, Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Amortized 2023 (Level 1) (Level 2) (Level 3) Cost Cash equivalents: Money Market Funds $ 54,154 $ 54,154 $ - $ - $ 54,154 December 31, Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Amortized 2022 (Level 1) (Level 2) (Level 3) Cost Cash equivalents: Money Market Funds $ 67,801 $ 67,801 $ - $ - $ 67,801

Note 5 - Inventories

Note 5 - Inventories	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventories Inventories consist of the following: June 30, December 31, 2023 2022 Raw materials $ 19,032 $ 20,535 Work-in-process 16,117 10,648 Finished goods 26,254 25,306 Total $ 61,403 $ 56,489 Inventories $ 42,604 $ 39,765 Other long-term assets 18,799 16,724 Total $ 61,403 $ 56,489 Inventories are stated net of inventory reserves of approximately $10.2 million and $9.9 million, as of June 30, 2023 December 31, 2022,

Note 6 - Acquired Intangible As

Note 6 - Acquired Intangible Assets, Net	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	6. Intangible Assets Intangible assets as of June 30, 2023 December 31, 2022 December 31, Six Months Ended June 30, 2023 2022 Less: Accumulated Weighted Currency Less: Average Gross Translation Accumulated Net Book Net Book Useful Value Adjustment Amortization Value Value Life Developed technology $ 89,580 $ (1,608 ) $ (26,584 ) $ 61,388 $ 64,286 15 IPR&D 2,656 (1,006 ) - 1,650 1,650 Indefinite Customer relationships 9,000 (3,077 ) 5,923 6,373 10 Distributor relationships 4,700 (415 ) (4,285 ) - - 5 Patents 1,000 (189 ) (704 ) 107 131 16 Tradenames 5,200 (3,561 ) 1,639 2,159 5 Total $ 112,136 $ (3,218 ) $ (38,211 ) $ 70,707 $ 74,599 13 The aggregate amortization expense related to intangible assets was $2.0 million and $1.9 million for the three June 30, 2023 2022, six June 30, 2023 2022,

Note 7 - Goodwill

Note 7 - Goodwill	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Goodwill Disclosure [Text Block]	7. Goodwill The Company assesses goodwill for impairment annually, or, under certain circumstances, more frequently, such as when events or changes in circumstances indicate there may Changes in the carrying value of goodwill for the six June 30, 2023 Six Months Ended June 30, 2023 Balance, beginning of period $ 7,339 Effect of foreign currency adjustments 128 Balance, ending of period $ 7,467

Note 8 - Accrued Expenses

Note 8 - Accrued Expenses	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	8. Accrued Expenses Accrued expenses consist of the following: June 30, December 31, 2023 2022 Compensation and related expenses $ 8,690 $ 11,303 Professional fees 2,802 3,145 Operating lease liability - current 2,085 2,073 Clinical trial costs 462 999 Income taxes payable 931 810 Other 542 510 Total $ 15,512 $ 18,840

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may not third June 30, 2023 December 31, 2022 no The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does not On October 21, 2021, April 24, 2023, March 31, 2023 April 2023.

Note 10 - Revenue and Geographi

Note 10 - Revenue and Geographic Information	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	10. Revenue and Geographic Information Revenue by product family is as follows: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 OA Pain Management $ 29,334 $ 24,093 $ 51,967 $ 45,058 Joint Preservation and Restoration 12,660 12,095 26,113 24,234 Non-Orthopedic 2,308 3,469 4,146 7,058 $ 44,302 $ 39,657 $ 82,226 $ 76,350 Effective January 1, 2023, three June 30, 2023 2022, six June 30, 2023 2022, Revenue from the Company’s sole significant customer, DePuy Synthes Mitek Sports Medicine, part of the Johnson & Johnson Medical Companies, as a percentage of the Company’s total revenue was 48% and 45% for the three June 30, 2023 2022, six June 30, 2023 2022, Total revenue by geographic location based on the location of the customer in total and as a percentage of total revenue were as follows: Three Months Ended June 30, 2023 2022 Percentage of Percentage of Revenue Revenue Revenue Revenue Geographic Location: United States $ 32,867 74 % $ 29,686 75 % Europe 5,675 13 % 5,292 13 % Other 5,760 13 % 4,679 12 % Total $ 44,302 100 % $ 39,657 100 % Six Months Ended June 30, 2023 2022 Percentage of Percentage of Revenue Revenue Revenue Revenue Geographic Location: United States $ 60,155 73 % $ 56,459 73 % Europe 11,337 14 % 11,088 15 % Other 10,734 13 % 8,803 12 % Total $ 82,226 100 % $ 76,350 100 %

Note 11 - Equity Incentive Plan

Note 11 - Equity Incentive Plan	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	11. Equity Incentive Plan Equity Incentive Plan The Anika Therapeutics, Inc. 2017 “2017 June 13, 2017 June 18, 2019, June 16, 2020, June 16, 2021, June 8, 2022 June 14, 2023. June 14, 2023, 2017 2017 may 2017 two no may 2017 June 30, 2023 2017 The Anika Therapeutics, Inc. 2021 November 4, 2021. may not 2017 June 30, 2023 The Company may three ten The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Cost of revenue $ 167 $ 227 $ 351 $ 403 Research & development 653 503 1,170 870 Selling, general & administrative 3,330 3,351 6,346 5,323 Total stock-based compensation expense $ 4,150 $ 4,081 $ 7,867 $ 6,626 Stock Options Stock options are granted to purchase common shares at prices that are equal to the fair market value of the shares on the date the options are granted or, in the case of premium options, are granted with an exercise price at 110% of the market price of the Company’s common stock on the date of grant. Options generally vest in equal annual installments over a period of three 10 The following summarizes the activity under the Company’s stock option plans: Weighted Average Weighted Remaining Aggregate Average Contractual Intrinsic Number of Exercise Term Value Options Price (in years) (in thousands) Outstanding as of December 31, 2022 1,530,703 $ 34.93 Granted 361,745 $ 29.51 Exercised (2,034 ) $ 18.30 $ 20 Forfeited and canceled (45,958 ) $ 36.61 Outstanding as of June 30, 2023 1,844,456 $ 33.84 8.0 $ 188 Vested, June 30, 2023 955,429 $ 36.75 7.1 $ 38 Vested or expected to vest, June 30, 2023 1,844,456 $ 33.84 8.0 $ 188 The aggregate intrinsic value of options exercised for the six June 30, 2023 six June 30, 2023. The Company uses the Black-Scholes pricing model to determine the fair value of options granted. The calculation of the fair value of stock options is affected by the stock price on the grant date, the expected volatility of the Company’s common stock over the expected term of the award, the expected life of the award, the risk-free interest rate and the dividend yield. The assumptions used in the Black-Scholes pricing model for options granted during the six June 30, 2023 2022, Six Months Ended June 30, 2023 2022 Risk free interest rate 3.5 % - 4.3 % 1.3 % - 3.0 % Expected volatility 48.7 % - 49.4 % 53.8 % - 55.2 % Expected life (years) 4.5 4.5 Expected dividend yield 0.0 % 0.0 % Fair value per option $ 11.74 $ 11.28 As of June 30, 2023, Restricted Stock Units RSUs generally vest in equal annual installments over a three RSU activity for the six June 30, 2023 Weighted Number of Average Shares Fair Value Outstanding as of December 31, 2022 675,405 $ 28.40 Granted 429,476 $ 26.93 Vested (247,369 ) $ 28.93 Forfeited and cancelled (34,098 ) $ 27.49 Outstanding as of June 30, 2023 823,414 $ 27.52 The weighted-average grant-date fair value per share of RSUs granted was $26.93 and $25.18 for the six June 30, 2023 2022, six June 30, 2023 2022, June 30, 2023, Performance Stock Units PSU activity for the six June 30, 2023 Number of Shares Weighted Average Fair Value Outstanding as of December 31, 2022 117,897 $ 34.98 Forfeited and cancelled (117,897 ) $ 34.98 Outstanding as of June 30, 2023 - $ - The total fair value of PSUs vested was $0 and $0.6 million for the six June 30, 2023 2022, June 30, 2023, no

Note 12 - Income Taxes

Note 12 - Income Taxes	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12. Income Taxes The Company recorded an income tax benefit of $0.3 million and $2.0 million for the three six June 30, 2023, three six June 30, 2022, The change in the effective tax rate for the three June 30, 2023, 2022, three June 30, 2022, three June 30, 2023. six June 30, 2023, 2022, six June 30, 2023, six June 30, 2022. The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not December 31, 2022, 2023. December 31, 2023 not not three six June 30, 2023 June 30, 2023, The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in certain foreign jurisdictions. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate, which varies by jurisdiction.

Note 13 - Share Repurchase

Note 13 - Share Repurchase	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Equity [Text Block]	13. Share Repurchase In April 2023, first second On May 12, 2023, May 12, 2023 June 30, 2023. July 2023. July 2023,

Note 14- Earnings Per Share ("E

Note 14- Earnings Per Share ("EPS")	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	14. Earnings Per Share ( EPS ) Basic EPS is calculated by dividing net income (loss) by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not The Company had a net loss during the three six June 30, 2023 2022, June 30, 2023 2022, June 30, 2023 2022. not

Other Information - Rule 10b5-1

Other Information - Rule 10b5-1 Trading Plans	6 Months Ended
	Jun. 30, 2023
Notes to Financial Statements
Issuer Rule 10b5-1, Material Terms [Text Block]	5. OTHER INFORMATION. Rule 10b5 1 During the fiscal quarter ended June 30, 2023, none 10b5 1 10b5 1

Note 3 - Accounts Receivable (T

Note 3 - Accounts Receivable (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	As of As of June 30, December 31, 2023 2022 Accounts Receivable $ 38,357 $ 36,235 Less: Allowance for credit losses 1,620 1,608 Net balance, end of period $ 36,737 $ 34,627 As of June 30, 2023 2022 Balance, beginning of the period $ 1,608 $ 1,442 Amounts provided 241 226 Amounts recovered (138 ) (48 ) Amounts written off (103 ) (111 ) Translation adjustments 12 (104 ) Balance, end of period $ 1,620 $ 1,405

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	June 30, Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Amortized 2023 (Level 1) (Level 2) (Level 3) Cost Cash equivalents: Money Market Funds $ 54,154 $ 54,154 $ - $ - $ 54,154 December 31, Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Amortized 2022 (Level 1) (Level 2) (Level 3) Cost Cash equivalents: Money Market Funds $ 67,801 $ 67,801 $ - $ - $ 67,801

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, December 31, 2023 2022 Raw materials $ 19,032 $ 20,535 Work-in-process 16,117 10,648 Finished goods 26,254 25,306 Total $ 61,403 $ 56,489 Inventories $ 42,604 $ 39,765 Other long-term assets 18,799 16,724 Total $ 61,403 $ 56,489

Note 6 - Acquired Intangible _2

Note 6 - Acquired Intangible Assets, Net (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]	December 31, Six Months Ended June 30, 2023 2022 Less: Accumulated Weighted Currency Less: Average Gross Translation Accumulated Net Book Net Book Useful Value Adjustment Amortization Value Value Life Developed technology $ 89,580 $ (1,608 ) $ (26,584 ) $ 61,388 $ 64,286 15 IPR&D 2,656 (1,006 ) - 1,650 1,650 Indefinite Customer relationships 9,000 (3,077 ) 5,923 6,373 10 Distributor relationships 4,700 (415 ) (4,285 ) - - 5 Patents 1,000 (189 ) (704 ) 107 131 16 Tradenames 5,200 (3,561 ) 1,639 2,159 5 Total $ 112,136 $ (3,218 ) $ (38,211 ) $ 70,707 $ 74,599 13

Note 7 - Goodwill (Tables)

Note 7 - Goodwill (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Goodwill [Table Text Block]	Six Months Ended June 30, 2023 Balance, beginning of period $ 7,339 Effect of foreign currency adjustments 128 Balance, ending of period $ 7,467

Note 8 - Accrued Expenses (Tabl

Note 8 - Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	June 30, December 31, 2023 2022 Compensation and related expenses $ 8,690 $ 11,303 Professional fees 2,802 3,145 Operating lease liability - current 2,085 2,073 Clinical trial costs 462 999 Income taxes payable 931 810 Other 542 510 Total $ 15,512 $ 18,840

Note 10 - Revenue and Geograp_2

Note 10 - Revenue and Geographic Information (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 OA Pain Management $ 29,334 $ 24,093 $ 51,967 $ 45,058 Joint Preservation and Restoration 12,660 12,095 26,113 24,234 Non-Orthopedic 2,308 3,469 4,146 7,058 $ 44,302 $ 39,657 $ 82,226 $ 76,350
Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]	Three Months Ended June 30, 2023 2022 Percentage of Percentage of Revenue Revenue Revenue Revenue Geographic Location: United States $ 32,867 74 % $ 29,686 75 % Europe 5,675 13 % 5,292 13 % Other 5,760 13 % 4,679 12 % Total $ 44,302 100 % $ 39,657 100 % Six Months Ended June 30, 2023 2022 Percentage of Percentage of Revenue Revenue Revenue Revenue Geographic Location: United States $ 60,155 73 % $ 56,459 73 % Europe 11,337 14 % 11,088 15 % Other 10,734 13 % 8,803 12 % Total $ 82,226 100 % $ 76,350 100 %

Note 11 - Equity Incentive Pl_2

Note 11 - Equity Incentive Plan (Tables)	6 Months Ended
	Jun. 30, 2023
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Cost of revenue $ 167 $ 227 $ 351 $ 403 Research & development 653 503 1,170 870 Selling, general & administrative 3,330 3,351 6,346 5,323 Total stock-based compensation expense $ 4,150 $ 4,081 $ 7,867 $ 6,626
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Weighted Remaining Aggregate Average Contractual Intrinsic Number of Exercise Term Value Options Price (in years) (in thousands) Outstanding as of December 31, 2022 1,530,703 $ 34.93 Granted 361,745 $ 29.51 Exercised (2,034 ) $ 18.30 $ 20 Forfeited and canceled (45,958 ) $ 36.61 Outstanding as of June 30, 2023 1,844,456 $ 33.84 8.0 $ 188 Vested, June 30, 2023 955,429 $ 36.75 7.1 $ 38 Vested or expected to vest, June 30, 2023 1,844,456 $ 33.84 8.0 $ 188
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Six Months Ended June 30, 2023 2022 Risk free interest rate 3.5 % - 4.3 % 1.3 % - 3.0 % Expected volatility 48.7 % - 49.4 % 53.8 % - 55.2 % Expected life (years) 4.5 4.5 Expected dividend yield 0.0 % 0.0 % Fair value per option $ 11.74 $ 11.28
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Weighted Number of Average Shares Fair Value Outstanding as of December 31, 2022 675,405 $ 28.40 Granted 429,476 $ 26.93 Vested (247,369 ) $ 28.93 Forfeited and cancelled (34,098 ) $ 27.49 Outstanding as of June 30, 2023 823,414 $ 27.52
Schedule of Nonvested Performance-Based Units Activity [Table Text Block]	Number of Shares Weighted Average Fair Value Outstanding as of December 31, 2022 117,897 $ 34.98 Forfeited and cancelled (117,897 ) $ 34.98 Outstanding as of June 30, 2023 - $ -

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation (Details Textual)	6 Months Ended
	Jun. 30, 2023
Number of Operating Segments	1

Note 3 - Accounts Receivable -

Note 3 - Accounts Receivable - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 01, 2022
Accounts Receivable	$ 38,357		$ 36,235
Less: Allowance for credit losses	1,620		1,608
Net balance, end of period	36,737		$ 34,627
Balance, beginning of the period	1,608	$ 1,442
Amounts provided	241	226
Amounts recovered	(138)	(48)
Amounts written off	(103)	(111)
Translation adjustments	12	(104)
Balance, end of period	$ 1,620	$ 1,405

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) - Money Market Funds [Member] - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Estimate of Fair Value Measurement [Member]
Cash equivalents	$ 54,154	$ 67,801
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents	54,154	67,801
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents	0	0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents	0	0
Reported Value Measurement [Member]
Cash equivalents	$ 54,154	$ 67,801

Note 5 - Inventories (Details T

Note 5 - Inventories (Details Textual) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Inventory Valuation Reserves	$ 10.2	$ 9.9

Note 5 - Inventories - Summary

Note 5 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Raw materials	$ 19,032	$ 20,535
Work-in-process	16,117	10,648
Finished goods	26,254	25,306
Total	61,403	56,489
Inventories	42,604	39,765
Other long-term assets	$ 18,799	$ 16,724

Note 6 - Acquired Intangible _3

Note 6 - Acquired Intangible Assets, Net (Details Textual) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Amortization of Intangible Assets	$ 2	$ 1.9	$ 3.9	$ 3.9

Note 6 - Acquired Intangible _4

Note 6 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Gross value	$ 112,136
Accumulated Currency Translation Adjustment	(3,218)
Current period impairment charge	(38,211)
Accumulated Amortization	70,707
Net book value	$ 70,707	$ 74,599
Useful life (Year)	13 years
Developed Technology Rights [Member]
Gross value	$ 89,580
Accumulated Currency Translation Adjustment	(1,608)
Current period impairment charge	(26,584)
Accumulated Amortization	$ 61,388
Net book value		64,286
Useful life (Year)	15 years
In Process Research and Development [Member]
Gross value	$ 2,656
Accumulated Currency Translation Adjustment	(1,006)
Current period impairment charge	0
Accumulated Amortization	1,650
Net book value		1,650
Customer Relationships [Member]
Gross value	9,000
Accumulated Currency Translation Adjustment
Current period impairment charge	(3,077)
Accumulated Amortization	$ 5,923
Net book value		6,373
Useful life (Year)	10 years
Distribution Rights [Member]
Gross value	$ 4,700
Accumulated Currency Translation Adjustment	(415)
Current period impairment charge	(4,285)
Accumulated Amortization	$ 0
Net book value		0
Useful life (Year)	5 years
Patents [Member]
Gross value	$ 1,000
Accumulated Currency Translation Adjustment	(189)
Current period impairment charge	(704)
Accumulated Amortization	$ 107
Net book value		131
Useful life (Year)	16 years
Trade Names [Member]
Gross value	$ 5,200
Accumulated Currency Translation Adjustment
Current period impairment charge	(3,561)
Accumulated Amortization	$ 1,639
Net book value		$ 2,159
Useful life (Year)	5 years

Note 7 - Goodwill - Changes in

Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Balance, beginning of period	$ 7,339
Effect of foreign currency adjustments	128
Balance, ending of period	$ 7,467

Note 8 - Accrued Expenses - Sum

Note 8 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Compensation and related expenses	$ 8,690	$ 11,303
Professional fees	2,802	3,145
Clinical trial costs	462	999
Income taxes payable	931	810
Other	542	510
Total	15,512	18,840
Accrued Expenses and Other Current Liabilities [Member]
Operating lease liability - current	$ 2,085	$ 2,073

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	Oct. 21, 2021	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Standard and Extended Product Warranty Accrual, Ending Balance		$ 0		$ 0
Parcus Medical Arbitration [Member]
Loss Contingency, Damages Sought, Value	$ 60,000
Parcus Medical Arbitration [Member] | Pending Litigation [Member]
Payments for Legal Settlements	$ 4,300
Loss Contingency Accrual			$ 3,300

Note 10 - Revenue and Geograp_3

Note 10 - Revenue and Geographic Information (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue from Contract with Customer, Excluding Assessed Tax	$ 44,302,000	$ 39,657,000	$ 82,226,000	$ 76,350,000
OA Pain Management [member]
Revenue from Contract with Customer, Excluding Assessed Tax	29,334,000	24,093,000	51,967,000	45,058,000
Veterinary [Member] | OA Pain Management [member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,100	$ 1,600	$ 1,600	$ 3,400
DePuy Synthes Mitek Sports Medicine [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage	48%	45%	46%	42%

Note 10 - Revenue and Geograp_4

Note 10 - Revenue and Geographic Information - Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue	$ 44,302	$ 39,657	$ 82,226	$ 76,350
OA Pain Management [member]
Revenue	29,334	24,093	51,967	45,058
Joint Preservation and Restoration [Member]
Revenue	12,660	12,095	26,113	24,234
Non-Orthopedic [Member]
Revenue	$ 2,308	$ 3,469	$ 4,146	$ 7,058

Note 10 - Revenue and Geograp_5

Note 10 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue	$ 44,302	$ 39,657	$ 82,226	$ 76,350
Percentage of Revenue	100%	100%	100%	100%
UNITED STATES
Revenue	$ 32,867	$ 29,686	$ 60,155	$ 56,459
Percentage of Revenue	74%	75%	73%	73%
Europe [Member]
Revenue	$ 5,675	$ 5,292	$ 11,337	$ 11,088
Percentage of Revenue	13%	13%	14%	15%
Other Location [Member]
Revenue	$ 5,760	$ 4,679	$ 10,734	$ 8,803
Percentage of Revenue	13%	12%	13%	12%

Note 11 - Equity Incentive Pl_3

Note 11 - Equity Incentive Plan (Details Textual) - USD ($) $ / shares in Units, $ in Millions		6 Months Ended
	Jun. 14, 2023	Jun. 30, 2023	Jun. 30, 2022	Jun. 13, 2023	Nov. 04, 2021	Jun. 13, 2017
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		361,745
Premium-Priced Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Premium Priced Options, Exercise Price as Percentage of Market Price		110%
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		10 years
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		$ 8.5
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		2 years
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		$ 17.9
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		2 years 1 month 6 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 26.93	$ 25.18
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value		$ 6.6	$ 5.4
Restricted Stock Units (RSUs) [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		3 years
Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value			$ 0.6
The 2017 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	435,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	5,285,000			4,850,000
Number of Shares Available for Grant Reduced By Each Share Award Issued Other Than Options or SARs (in shares)						2
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)		800,000				5,285,000
The 2021 Inducement Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)		10,374
Common Stock, Capital Shares Reserved for Future Issuance (in shares)					125,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)		3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)		10 years

Note 11 - Equity Incentive Pl_4

Note 11 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Stock-based compensation expense	$ 4,150	$ 4,081	$ 7,867	$ 6,626
Cost of Sales [Member]
Stock-based compensation expense	167	227	351	403
Research and Development Expense [Member]
Stock-based compensation expense	653	503	1,170	870
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 3,330	$ 3,351	$ 6,346	$ 5,323

Note 11 - Equity Incentive Pl_5

Note 11 - Equity Incentive Plan - Stock Options (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Outstanding, shares (in shares) | shares	1,530,703
Outstanding, Weighted Average Exercise (in dollars per share) | $ / shares	$ 34.93
Granted, shares (in shares) | shares	361,745
Granted, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 29.51
Exercised, shares (in shares) | shares	(2,034)
Exercised, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 18.30
Exercised, Aggregate Intrinsic Value | $	$ 20
Forfeited and canceled, shares (in shares) | shares	(45,958)
Forfeited and canceled, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 36.61
Outstanding, shares (in shares) | shares	1,844,456
Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 33.84
Outstanding, Weighted Average Remaining Contractual Term (Year)	8 years
Outstanding, Aggregate Intrinsic Value | $	$ 188
Vested, shares (in shares) | shares	955,429
Vested, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 36.75
Vested, Weighted Average Remaining Contractual Term (Year)	7 years 1 month 6 days
Vested, Aggregate Intrinsic Value | $	$ 38
Vested and expected to vest, shares (in shares) | shares	1,844,456
Vested and expected to vest, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 33.84
Vested and expected to vest, Weighted Average Remaining Contractual Term (Year)	8 years
Vested and expected to vest, Aggregate Intrinsic Value | $	$ 188

Note 11 - Equity Incentive Pl_6

Note 11 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Expected life (years) (Year)	4 years 6 months	4 years 6 months
Expected dividend yield	0%	0%
Fair value per option	0.1174	0.1128
Minimum [Member]
Risk free interest rate	3.50%	1.30%
Expected volatility	48.70%	53.80%
Maximum [Member]
Risk free interest rate	4.30%	3%
Expected volatility	49.40%	55.20%

Note 11 - Equity Incentive Pl_7

Note 11 - Equity Incentive Plan - Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Outstanding, shares (in shares)	675,405
Outstanding, weighted average grant date fair value (in dollars per share)	$ 28.40
Granted (in shares)	429,476
Granted, weighted average grant date fair value (in dollars per share)	$ 26.93	$ 25.18
Vested, shares (in shares)	(247,369)
Vested, weighted average grant date fair value (in dollars per share)	$ 28.93
Forfeited and cancelled, shares (in shares)	(34,098)
Forfeited and cancelled, weighted average grant date fair value (in dollars per share)	$ 27.49
Outstanding, shares (in shares)	823,414
Outstanding, weighted average grant date fair value (in dollars per share)	$ 27.52

Note 11 - Equity Incentive Pl_8

Note 11 - Equity Incentive Plan - Performance Stock Units (Details) - Performance Shares [Member]	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Outstanding, shares (in shares) | shares	117,897
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 34.98
Forfeited and cancelled, shares (in shares) | shares	(117,897)
Forfeited and cancelled, weighted average grant date fair value (in dollars per share) | $ / shares	$ 34.98
Outstanding, shares (in shares) | shares	0
Outstanding, weighted average grant date fair value (in dollars per share) | $ / shares	$ 0

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Expense (Benefit)	$ (329)	$ (442)	$ (1,993)	$ (1,217)
Effective Income Tax Rate Reconciliation, Percent	10.70%	13.50%	13.20%	17.40%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount				$ 600
Deferred Tax Assets, Valuation Allowance	$ 1,200		$ 1,200
Domestic Tax Authority [Member] | Change in Effective Tax Rate Due to Discrete Non-deductible Stock Compensation Charge [Member]
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount		$ 400
Deferred Tax Assets, Valuation Allowance	$ 300		$ 300

Note 13 - Share Repurchase (Det

Note 13 - Share Repurchase (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended	6 Months Ended
	May 12, 2023	Jul. 31, 2023	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Apr. 30, 2023	Apr. 13, 2023
Payments for Repurchase of Common Stock				$ 5,000	$ 0
Cooperation Agreement [Member]
Stock Repurchase Program, Authorized Amount							$ 20,000
Cooperation Agreement [Member] | Accelerated Stock Repurchase Program with Investment Bank [Member]
Stock Repurchase Program, Authorized Amount						$ 5,000
Cooperation Agreement [Member] | Stock Repurchase Program on Open Market [Member]
Stock Repurchase Program, Authorized Amount						5,000
Cooperation Agreement [Member] | Stock Repurchase Program on Open Market Subject to Positive Cash Flow[Member]
Stock Repurchase Program, Authorized Amount						$ 10,000
Accelerated Stock Repurchase Agreement [Member] | Fixed Dollar Accelerated Share Repurchase Transaction (“ASR Agreement”) [Member] | Bank of America [Member]
Stock Repurchase Program, Authorized Amount	$ 5,000
Payments for Repurchase of Common Stock	$ 5,000
Stock Repurchased During Period, Shares (in shares)	158,983	29,046
Accelerated Share Repurchases, Initial Price Paid Per Share (in dollars per share)	$ 25.16
Accelerated Share Repurchases, Percentage of Shares Repurchased	80%
Accelerated Share Repurchases, Final Price Paid Per Share (in dollars per share)		$ 26.59
Accelerated Stock Repurchase Agreement [Member] | Fixed Dollar Accelerated Share Repurchase Transaction (“ASR Agreement”) [Member] | Bank of America [Member] | Additional Paid-in Capital [Member]
Treasury Stock, Value, Acquired, Par Value Method			$ 5,000

Note 14- Earnings Per Share (_2

Note 14- Earnings Per Share ("EPS") (Details Textual) - shares shares in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1.8	1.5
Restricted Stock Units and Performance Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	0.8	0.8